US aid freeze could set back Africa’s fight against HIV by years, researchers warn
Trump’s pause in USAID spending has put major African HIV vaccine and prevention trials on hold, leaving the research world in shock
Related Articles
New Molecule Used in Cancer Treatment Shows Promise for Treating HIV
Learn how the molecule EBC-46 could advance how HIV is treated and how researchers discovered it.
A Call for Action: Lessons Learned From a Pilot to Share a Complex, Linked COVID-19 Cohort Dataset for Open Science
The COVID-19 pandemic proved how sharing of genomic sequences in a timely manner, as well as early detection and surveillance of variants and characterisation of…
Bacteriophage therapy reduces Staphylococcus aureus in a porcine and human ex vivo burn wound infection model | Antimicrobial Agents and Chemotherapy
Annually, an estimated 11 million people require medical treatment for burn wounds globally. Mortality rates of burn wounds requiring treatment are high and can even…
Endoscope-associated outbreak of OXA-181-carbapenemase-producing Klebsiella pneumoniae and its implications for hygiene management
To report the epidemiologic, microbiologic and genetic investigation of a large outbreak of carbapenem-resistant Klebsiella pneumoniae associated with gastrointestinal endoscopy, including infection control interventions.
RFK Jr. says vaccines aren’t tested enough. Experts say that’s baseless.
RFK Jr.’s views on vaccine safety have sparked debate, with some experts saying that his comments are misleading.
How the gutting of USAID is reverberating around the world: Worry, despair, praise
Reactions to the changes in USAID run the gamut. Some leading voices — like Mexico’s president — are in favor. Others fear that lives will…
One dead, eight sickened in Uganda’s new Ebola outbreak
Uganda’s Health Ministry has confirmed nine Ebola cases in the country.
Assisted dying’s safeguards were always a sham
For the MPs Leadbeater and her allies misled, now is surely time to re-evaluate their position
People with immune impairment accounted for 22% of COVID hospital stays, deaths, study suggests
Immunocompromised participants were much more likely to have received at least four doses of COVID-19 vaccine than their otherwise healthy peers (73% vs. 30%).
CEPI awards $5 million to company developing nasal RNA vaccines
Nasal administration could help to achieve mucosal immunity.